Rubius Therapeutics goes public
Cambridge, Massachusetts-based Rubius Therapeutics, a creator of cellular therapies, has debuted its IPO after pricing its over 10.4 million shares at $23 per share. The stock began trading July 18, 2018 on the NASDAQ under the ticker symbol "RUBY." J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners are the lead underwriters. Rubius' pre-IPO backers include Flagship Pioneering.
18 July 2018•2 mins read
